Physician profile
Stephen Z Smith
NPI 1235138009
$5,557.36
in general payments reported to CMS, 2019-2025
22 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $514 · 2021: $914 · 2022: $512 · 2023: $604 · 2024: $828 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.54 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $1,290.30 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $795.51 | 2020-2021 | |
| Abbvie INC. | $531.21 | 2021-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $511.57 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $499.86 | 2022-2024 | Vtama |
| Genzyme Corporation | $350.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $255.23 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $213.97 | 2022-2025 | Tremfya |
| Prugen, INC. Pharmaceuticals | $210.00 | 2021 | |
| Incyte Corporation | $159.65 | 2022-2023 | Opzelura |
| Lilly USA, LLC | $127.92 | 2022-2023 | Taltz, Olumiant |
| Epi Health, LLC | $106.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.96 | 2024-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $66.86 | 2020-2024 | |
| Organon LLC | $62.73 | 2025 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $56.50 | 2021-2023 | Winlevi, Absorica Ld |
| Amgen INC. | $55.28 | 2024-2025 | Otezla, Otezla |
| Smith+Nephew, INC. | $49.64 | 2024 | Grafix, Stravix |
| Kyowa Kirin, INC. | $41.67 | 2022-2025 | |
| Sebela Pharmaceuticals INC. | $39.61 | 2023 | Pramosone, Naftin |
| Regeneron Healthcare Solutions, INC. | $24.88 | 2023 | Libtayo |
| Pfizer INC. | $19.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.